Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Hedefe Yönelik Tedaviler

Yazarlar

Engin Çeşmeci
https://orcid.org/0000-0002-2158-9075

Özet

Moleküler olarak seçilmiş hedefe yönelik tedaviler, erken evre küçük hücreli dışı akciğer kanserinin (KHDAK) küratif amaçlı multimodal tedavisinin temel bileşenlerinden biri hâline gelmiştir. Tam rezeksiyon sonrasında EGFR ekzon 19 delesyonu veya L858R mutasyonu taşıyan hastalarda adjuvan osimertinib genel sağkalım yararı, ALK rearanjmanlı hastalarda adjuvan alektinib ise kemoterapiye göre belirgin hastalıksız sağkalım yararı sağlamıştır. Son dönemde ELEVATE çalışması kemoterapi sonrası adjuvan ensartinibin, LIBRETTO-432 çalışması RET füzyonu pozitif hastalıkta adjuvan selperkatinibin etkinliğini göstermiş; NeoADAURA çalışması neoadjuvan osimertinibin majör patolojik yanıt üzerindeki üstünlüğünü ortaya koymuştur. Rezeke edilemeyen evre III hastalıkta ise LAURA çalışması kemoradyoterapi sonrası osimertinib konsolidasyonunun progresyonsuz sağkalımı belirgin biçimde uzattığını göstermiştir. Bu gelişmeler, moleküler testin nüks aşamasına ertelenmeden perioperatif tedavi kararından önce yapılmasını zorunlu kılmaktadır. Bu bölümde epidemiyoloji, moleküler tanı, alt tiplerin biyolojik özellikleri ve randomize çalışma kanıtları evre I, II ve III çerçevesinde ele alınmakta; çalışmaların özgün evreleme sürümleri, kontrol kolları, sonlanım noktaları ve genellenebilirlik sınırları korunmaktadır. Kongre verileri ile tam yayınlar ayrı değerlendirilmiş, çalışmalar arasında dolaylı üstünlük karşılaştırması yapılmamıştır. Bölümde üç evreye özgü karar algoritması ve güncel çalışmaların karşılaştırmalı tabloları sunulmaktadır. ROS1, MET, BRAF, ERBB2, NTRK ve KRAS değişikliklerinde metastatik hastalıktaki etkinlik ile erken evrede kanıtlanmış yarar birbirinden ayrılmaktadır. Moleküler rezidüel hastalık, tedavi süresi, toksisite, direnç ve izlem de ayrıca tartışılmaktadır. Tedavi seçimi anatomik risk, doğrulanmış prediktif biyobelirteç, uygun karşılaştırmalı kanıt ve hasta tercihlerinin birlikte değerlendirilmesini gerektirmekte; kılavuz önerileri ise ruhsat ve geri ödeme koşullarından ayrı ele alınmalıdır. Gelecekteki temel sorular, tedavinin hangi hastada yoğunlaştırılacağı, kimde güvenle azaltılabileceği ve nadir moleküler alt gruplarda kür olasılığının nasıl artırılacağıdır.

 

Referanslar

Tsuboi M, Herbst RS, John T, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. New England Journal of Medicine. 2023;389(2): 137–147. doi:10.1056/nejmoa2304594

Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(14): 1265–1276. doi:10.1056/nejmoa2310532

Wu YL, Hochmair M, Yang Y, et al. Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395(7): 660–670. doi:10.1056/nejmoa2602628

Zer A, Ahn MJ, Barlesi F, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2025;36(11): 1245–1262. doi:10.1016/j.annonc.2025.08.003

Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2020;383(18): 1711–1723. doi:10.1056/nejmoa2027071

Yue D, Huang M, Song P, et al. Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395(2): 151–161. doi:10.1056/nejmoa2518990

Dziadziuszko R, Solomon BJ, Wu YL, et al. 1787MO Updated Results From the Phase III ALINA Study of Adjuvant Alectinib vs Chemotherapy (Chemo) in Patients (Pts) With Early-Stage ALK+ Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 2025;36: S971–S972. doi:10.1016/j.annonc.2025.08.2413

Zhang C, Hu Y, Jiang BY, et al. Neoadjuvant Lorlatinib in Stage III NSCLC Harboring ALK Fusion: A Phase 2 Multicenter Study (LORIN). Journal of Clinical Oncology. 2026;44(16_suppl): 8002. doi:10.1200/jco.2026.44.16_suppl.8002

Wu YL, Majem M, John T, et al. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial. Journal of Thoracic Oncology. 2026: 104179. doi:10.1016/j.jtho.2026.104179

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3): 229–263. doi:10.3322/caac.21834

Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Journal of Thoracic Oncology. 2018;13(3): 323–358. doi:10.1016/j.jtho.2017.12.001

Bossé Y, Boudreau DK, Saavedra Armero V, et al. Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project. Lung Cancer. 2025;203: 108530. doi:10.1016/j.lungcan.2025.108530

Soo RA, Reungwetwattana T, Perroud HA, et al. Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study. Journal of Thoracic Oncology. 2024;19(10): 1449–1459. doi:10.1016/j.jtho.2024.06.008

Pi C, Xu CR, Zhang MF, et al. EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thoracic Cancer. 2018;9(7): 814–819. doi:10.1111/1759-7714.12651

Hondelink LM, Ernst SM, Atmodimedjo P, et al. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. European Journal of Cancer. 2023;181: 53–61. doi:10.1016/j.ejca.2022.12.010

Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. Journal of Clinical Oncology. 2022;40(6): 611–625. doi:10.1200/jco.21.01626

Olmedo ME, Cervera R, Cabezon-Gutierrez L, et al. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. World Journal of Clinical Oncology. 2022;13(4): 276–286. doi:10.5306/wjco.v13.i4.276

Abbosh C, Frankell AM, Harrison T, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957): 553–562. doi:10.1038/s41586-023-05776-4

Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery. 2017;7(12): 1394–1403. doi:10.1158/2159-8290.cd-17-0716

Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. Journal of Clinical Oncology. 2024;42(26): 3105–3114. doi:10.1200/jco.24.00071

Herbst RS, John T, Grohé C, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nature Medicine. 2025;31(6): 1958–1968. doi:10.1038/s41591-025-03577-y

Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(2): 118–131. doi:10.1056/nejmoa2302299

Zhou C, Solomon B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. New England Journal of Medicine. 2023;389(20): 1839–1850. doi:10.1056/nejmoa2309457

Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. New England Journal of Medicine. 2021;384(25): 2371–2381. doi:10.1056/nejmoa2103695

Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. New England Journal of Medicine. 2022;387(2): 120–131. doi:10.1056/nejmoa2204619

Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2020;383(10): 944–957. doi:10.1056/nejmoa2002787

Planchard D, Smit EF, Groen HJM, et al. Dabrafenib Plus Trametinib in Patients With Previously Untreated BRAFV600E-mutant Metastatic Non-Small-Cell Lung Cancer: An Open-Label, Phase 2 Trial. The Lancet Oncology. 2017;18(10): 1307–1316. doi:10.1016/s1470-2045(17)30679-4

Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2022;386(3): 241–251. doi:10.1056/nejmoa2112431

Ghazali N, Feng J, Hueniken K, et al. Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241308466

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 9.2026. 2026. (28/09/2026 tarihinde https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf adresinden ulaşılmıştır).

Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of Clinical Oncology. 2023;41(10): 1830–1840. doi:10.1200/jco.22.02186

Tsutani Y, Goldman JW, Dacic S, et al. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023;24(4): 376–380. doi:10.1016/j.cllc.2023.02.002

ClinicalTrials.gov. A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (NCT05120349). 2026. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT05120349 adresinden ulaşılmıştır).

Pisters K, Kris MG, Gaspar LE, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2022;40(10): 1127–1129. doi:10.1200/JCO.22.00051

Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology. 2008;26(21): 3552–3559. doi:10.1200/jco.2007.13.9030

Singh N, Daly ME, Ismaila N, et al. Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2023;41(27): 4430–4432. doi:10.1200/JCO.23.01261

He J, Tsuboi M, Weder W, et al. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Clinical Oncology. 2025;43(26): 2875–2887. doi:10.1200/jco-25-00883

Puri S, Leighl NB, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0. Journal of Clinical Oncology. 2026;44(7). doi:10.1200/jco-25-02822

Travis WD, Dacic S, Wistuba I, et al. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology. 2020;15(5): 709–740. doi:10.1016/j.jtho.2020.01.005

Zhong WZ, Yan HH, Chen KN, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduction and Targeted Therapy. 2023;8(1). doi:10.1038/s41392-022-01286-3

Lu S, Kato T, Dong X, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. New England Journal of Medicine. 2024;391(7): 585–597. doi:10.1056/nejmoa2402614

Daly ME, Singh N, Ismaila N, et al. Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2024;42(25): 3058–3060. doi:10.1200/JCO-24-01324

Yu J, Meng X, Ge H, et al. PL04.13 Aumolertinib Maintenance after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer: Interim Results of the Phase III Study (POLESTAR). Journal of Thoracic Oncology. 2024;19(10): S6–S7. doi:10.1016/j.jtho.2024.09.021

Bi N, Wang J, Jiang W, et al. Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation. Signal Transduction and Targeted Therapy. 2026;11(1): 395. doi:10.1038/s41392-026-02891-2

Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. Journal of Clinical Oncology. 2013;31(27): 3320–3326. doi:10.1200/jco.2013.51.1816

Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 2015;33(34): 4007–4014. doi:10.1200/jco.2015.61.8918

Pennell NA, Neal JW, Chaft JE, et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2019;37(2): 97–104. doi:10.1200/jco.18.00131

Zhong WZ, Wang Q, Mao WM, et al. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. Journal of Clinical Oncology. 2021;39(7): 713–722. doi:10.1200/jco.20.01820

Yue D, Xu S, Wang Q, et al. Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy in Chinese Patients With Stage IIIA EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EVAN): A Randomised, Open-Label, Phase 2 Trial. The Lancet Respiratory Medicine. 2018;6(11): 863–873. doi:10.1016/s2213-2600(18)30277-7

He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. The Lancet Respiratory Medicine. 2021;9(9): 1021–1029. doi:10.1016/s2213-2600(21)00134-x

Tada H, Mitsudomi T, Misumi T, et al. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). Journal of Clinical Oncology. 2022;40(3): 231–241. doi:10.1200/jco.21.01729

ClinicalTrials.gov. A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (NCT05526755). 2026. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT05526755 adresinden ulaşılmıştır).

Osarogiagbon RU, Cetnar JP, Aljumaily R. Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-518244

Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. New England Journal of Medicine. 2023;389(22): 2039–2051. doi:10.1056/nejmoa2306441

US Food and Drug Administration. Alecensa prescribing information. 2024. (28/09/2026 tarihinde https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf adresinden ulaşılmıştır).

Leonetti A, Boni L, Gnetti L, et al. Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III ALK-positive NSCLC: Final Analysis of ALNEO Phase II Trial (GOIRC-01-2020-ML42316). Journal of Clinical Oncology. 2025;43(16_suppl): 8015. doi:10.1200/jco.2025.43.16_suppl.8015

ClinicalTrials.gov. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (NCT04302025). 2026. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04302025 adresinden ulaşılmıştır).

Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine. 2020;383(10): 931–943. doi:10.1056/nejmoa2004407

ClinicalTrials.gov. Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (NCT04926831). 2025. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04926831 adresinden ulaşılmıştır).

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. New England Journal of Medicine. 2018;378(8): 731–739. doi:10.1056/nejmoa1714448

Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of Oncology. 2019;30(5): 839–844. doi:10.1093/annonc/mdz077

Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. Clinical Pharmacology & Therapeutics. 2015;97(5): 447–450. doi:10.1002/cpt.91

ClinicalTrials.gov. To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (NCT04853342). 2026. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04853342 adresinden ulaşılmıştır).

ClinicalTrials.gov. Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations (NCT04687241). 2024. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04687241 adresinden ulaşılmıştır).

Matsumura Y, Yoh K, Zenke Y, et al. Initial Results of a Screening Trial for Evaluating Oncogenic Drivers in Japanese Patients With Surgically Resected Early-Stage Non-Small Cell Lung Cancer: LC-SCRUM-Advantage. Journal of Clinical Oncology. 2025;43(16_suppl): 8065. doi:10.1200/jco.2025.43.16_suppl.8065

Yayınlanan

16 Kasım 2026

Lisans

Lisans